Longevity of Humoral Response Six Months Following BNT162b2 Vaccine in Dialysis Patients

BACKGROUND: End-stage kidney disease substantially increases the risk of severe COVID-19. However, despite early robust immunogenicity of the mRNA-SARS-CoV-2 vaccination in patients with hemodialysis, the longevity of humoral response in this high-risk population is still unknown. METHODS: A prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Agur, Timna, Ben-Dor, Naomi, Herman-Edelstein, Michal, Steinmetz, Tali, Lichtenberg, Shelly, Schneider, Shira, Yahav, Dafna, Rozen-Zvi, Benaya, Zingerman, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990786/
https://www.ncbi.nlm.nih.gov/pubmed/35402451
http://dx.doi.org/10.3389/fmed.2022.781888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990786/
https://www.ncbi.nlm.nih.gov/pubmed/35402451
http://dx.doi.org/10.3389/fmed.2022.781888

Ejemplares similares